Hormone Optimization FAQ: Your Questions Answered

Hormone optimization is one of the most impactful interventions available for adults experiencing the effects of hormonal decline — but it also raises many questions. Here are honest, evidence-based answers to the questions we hear most often.

Hormone optimization is the process of assessing your hormonal status through comprehensive testing and, when deficiencies or imbalances are identified, restoring hormones to levels that support optimal health and function — not just the absence of disease.

This is distinct from "hormone replacement therapy" in the traditional sense, which aimed to replace hormones to premenopausal or pre-andropause levels. Hormone optimization aims for the levels at which you feel and function your best, which may be different for each individual.

Adults who are experiencing symptoms consistent with hormonal decline — fatigue, reduced libido, mood changes, brain fog, body composition changes, sleep disruption — and who have laboratory evidence of hormonal deficiency or imbalance.

Age is not the primary criterion. Some people in their 30s have significant hormonal deficiencies; some people in their 60s have adequate levels. Testing determines candidacy, not age alone.

Hormone optimization is one component of a comprehensive approach to healthy aging. Declining hormones are both a marker and driver of biological aging — addressing them is a genuine longevity intervention. But hormone optimization is most effective as part of a comprehensive approach that also addresses nutrition, exercise, sleep, and other lifestyle factors.

A comprehensive baseline evaluation should include:

• Hormonal panel: Testosterone (total and free), estradiol, progesterone (women), DHEA-S, LH, FSH
• Thyroid panel: TSH, free T3, free T4, reverse T3
• Metabolic panel: Fasting glucose, insulin, HbA1c, comprehensive metabolic panel
• Complete blood count: Baseline hematocrit (important for testosterone therapy)
• PSA: Baseline for men over 40 before testosterone therapy
• Lipid panel: Baseline cardiovascular risk assessment

Typically at 6–8 weeks after starting or adjusting therapy, then every 3–6 months once stable. The frequency depends on the specific hormones being optimized and your individual response.

Standard reference ranges are based on population averages — they define "normal" as the middle 95% of the tested population. This includes many symptomatic people. "Normal" doesn't mean optimal for you.

A man with testosterone of 310 ng/dL is technically "normal" but may be profoundly symptomatic if his personal optimal is 700 ng/dL. We interpret your results in the context of your symptoms and goals, not just whether they fall within a population range.

When properly managed, testosterone therapy has an excellent safety profile. Concerns about cardiovascular risk were based on early, poorly designed studies. More recent research — including the TRAVERSE trial — shows that testosterone therapy does not increase cardiovascular risk in men with hypogonadism and may actually improve cardiovascular outcomes.

Monitoring is important: hematocrit (testosterone can increase red blood cell production), PSA (testosterone can stimulate prostate growth), and estradiol (testosterone converts to estrogen) should be checked regularly.

Exogenous testosterone suppresses the body's own testosterone production and can significantly reduce sperm production. Men who wish to preserve fertility should discuss alternatives (clomiphene, HCG) with their provider before starting testosterone therapy.

• Injections (intramuscular or subcutaneous): Most cost-effective; typically weekly or twice-weekly
• Topical gels or creams: Convenient; risk of transfer to partners/children
• Pellet implants: Inserted subcutaneously every 3–6 months; consistent levels

Most men notice improvements in energy and mood within 2–4 weeks. Libido improvements typically follow at 4–6 weeks. Body composition changes (more muscle, less fat) take 3–6 months of consistent therapy.

The safety of hormone therapy for women has been significantly clarified since the Women's Health Initiative (WHI) study generated concern in 2002. The WHI used synthetic hormones in older women (average age 63) who were well past menopause — a very different population from women in early perimenopause.

Modern bioidentical hormone therapy, initiated in women under 60 or within 10 years of menopause, has a favorable benefit-risk profile for most women. The risks are different for different women — a thorough individual risk assessment is essential.

Bioidentical hormones are chemically identical to the hormones produced by the human body. They include estradiol (E2), estriol (E3), progesterone, testosterone, and DHEA. They are derived from plant sources (typically yam or soy) and processed to be structurally identical to human hormones.

Bioidentical hormones are available in FDA-approved formulations (Estrace, Prometrium, etc.) and in compounded formulations customized to individual needs.

This is a common concern, but the evidence suggests the opposite: hormone therapy, particularly when it includes testosterone, tends to improve body composition — supporting muscle mass and reducing fat, particularly visceral fat.

The weight gain often associated with menopause is driven by the hormonal changes themselves — not by hormone therapy. Addressing the hormonal changes with therapy typically improves body composition.

The best way to determine whether hormone optimization is appropriate for you is a comprehensive consultation and laboratory evaluation. If you're experiencing symptoms consistent with hormonal decline — fatigue, reduced libido, mood changes, brain fog, body composition changes — it's worth investigating.

Book a Hormone Consultation to get a comprehensive evaluation and honest assessment of whether hormone optimization is right for you.